Drug Trial Radar · NCT07950462
A Phase 1 Study of QLS7402 Injection in Adult Participants With Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jan 13, 2027
Primary completion
Oct 29, 2027
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTDIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending dose of QLS7402 injection administered subcutaneously in adult participants with overweight or obesity
Conditions
- Overweight or Obesity
Interventions
QLS7402 InjectionDrug
QLS7402 Injection
Placebo controlDrug
Placebo Control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs)Time frame: 169 days
- Number of participants with treatment-related adverse events (TRAEs)Time frame: 169 days
- Number of participants with serious adverse events (SAEs)Time frame: 169 days
- Number of participants with abnormal physical examination, 12-lead ECG and clinical laboratory testsTime frame: 169 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.